Choose a set of compounds. The Stack Builder shows the evidence grade of each one, the categories they span, and their regulatory status.
Semaglutide
Metabolic
Semaglutide is a GLP-1 receptor agonist. The FDA approves it for type 2 diabetes and for chronic weight management.
Tirzepatide
Tirzepatide is a dual GIP and GLP-1 receptor agonist. The FDA approved it on 13 May 2022.
Retatrutide
Retatrutide is an investigational triple receptor agonist. No regulator approves it. Phase 3 work continues.
AOD-9604
AOD-9604 is a modified growth hormone fragment. Six human trials ran. The Phase 2B trial failed its endpoint.
HGH Fragment 176-191
HGH Fragment 176-191 is a growth hormone fragment with animal data only. No human trial tested it.
MOTS-c
MOTS-c is a mitochondrial-derived peptide. Animal data support the metabolic mechanism. Human data are observational.
Tesamorelin
Growth Hormone
Tesamorelin is a growth hormone-releasing factor analog. The FDA approves it for one indication only.
Sermorelin
Sermorelin is a GHRH 1-29 analog. It held FDA approval as a diagnostic agent until 2008.
CJC-1295
CJC-1295 is a GHRH analog. Two different forms exist. Only Phase 1 human data support it.
Ipamorelin
Ipamorelin is a selective growth hormone secretagogue. Human pharmacokinetic data exist. No outcome trial exists.
GHRP-2
GHRP-2 is a growth hormone secretagogue. Japan approves it as a single-dose diagnostic agent.
GHRP-6
GHRP-6 is the first growth hormone releasing peptide. It causes the strongest appetite effect in its class.
Hexarelin
Hexarelin is a growth hormone secretagogue with a second cardiac action. Development stopped in about 2005.
IGF-1 LR3
IGF-1 LR3 is a research reagent. No dedicated human trial exists. Low blood glucose is the main acute risk.
BPC-157
Recovery
BPC-157 is a synthetic pentadecapeptide. The animal literature is large. The human record is one uncontrolled report.
TB-500
TB-500 is a marketed fragment of Thymosin beta-4. Human trials tested the full-length protein, not this fragment.
GHK-Cu
GHK-Cu is a copper tripeptide. Human evidence covers topical use. No clinical study covers the injectable form.
Epithalon
Longevity
Epithalon is a synthetic tetrapeptide. The evidence comes largely from one research group and lacks independent replication.
Humanin
Humanin is a mitochondrial-derived peptide. The preclinical record is robust. No interventional human trial exists.
Elamipretide (SS-31)
Elamipretide is a mitochondria-targeted tetrapeptide. The FDA approved it for Barth syndrome in September 2025.
FOXO4-DRI
FOXO4-DRI is a senolytic research reagent. Mouse data exist. No human trial exists.
Selank
Cognitive
Selank is a synthetic heptapeptide. Russia approves it for generalized anxiety disorder. Western data are thin.
Semax
Semax is a synthetic heptapeptide. Russia approves it and lists it as an essential drug. Western trial data are limited.
Dihexa
Dihexa is an angiotensin IV analog with animal data only. A retraction weakens its main mechanism claim.
DSIP (Delta Sleep-Inducing Peptide)
DSIP is a natural nonapeptide. Human trials are small and mixed. Reviews contest the sleep-factor hypothesis.
Pinealon
Pinealon is a synthetic tripeptide. All research comes from one institute. No human trial exists.
Thymosin Alpha-1
Immune
Thymosin Alpha-1 is a thymic peptide. More than 35 countries approve it. The FDA does not.
KPV
KPV is a tripeptide fragment of alpha-MSH. Mouse colitis data are strong. No human trial finished.
Melanotan I (Afamelanotide)
Melanocortin
Afamelanotide is an approved melanocortin receptor agonist. It treats erythropoietic protoporphyria.
Melanotan II
Melanotan II is an unapproved melanocortin agonist. Indexed case reports document serious harms.
Research stack · readout
Next step
Source only from transparent, third-party-tested vendors.
Educational planning tool only. No dosing guidance is provided and nothing here is medical advice. Consult a licensed clinician.
The Stack Builder shows evidence and regulatory status. It gives no dose, no schedule and no combination advice.